Eli Lilly & Co
LLY- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000059478
In the last 90 days, Eli Lilly & Co insiders filed 0 open-market purchases and 3 sales; 4,644 institutions reported holding it in 13F filings for Q2 2026, worth $942.7B in total; 4 superinvestors hold it, including ARK Invest and Soros Fund Management.
Q1 2023 vs. Q4 2022
How the institutions holding Eli Lilly & Co changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Of which not filed for Q1 2023 | Q1 2023 | Change |
|---|---|---|---|---|
| Holders | 2,672 | 56 | 2,619 | +3 |
| Shares | 790.2M | 938.6K | 840.7M | +51.5M (+6.5%) |
| Value | $288.4B | $309.6M | $269.7B | −$18.4B (−6.4%) |
56 institutions that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (155)
Institutions that held Eli Lilly & Co at the end of Q1 2023 but not at the end of Q4 2022.
Showing the largest 100 of 155 by value.
Sold out (152)
Institutions that held Eli Lilly & Co at the end of Q4 2022 and filed for Q1 2023 without it.
Showing the largest 100 of 152 by value.
Not filed for Q1 2023 yet (56)
Institutions that held Eli Lilly & Co at the end of Q4 2022 and haven't filed a 13F for Q1 2023. Not filing isn't selling, so they aren't counted as sold out.